Researchers from the University of Maryland presented preclinical data for YA-6060, a novel small molecule showing dual activities of Wnt inhibition and AMPK activation via the mechanism of AXIN stabilization. Since both Wnt/β-catenin and AMPK signaling pathways have been previously shown to play a key role in liver fibrosis, this study aimed to assess the potential of YA-6060 as an antifibrosis agent.